The Advocate Releases 2024 US Focused Patient Advocacy Report Highlighting Pharmaceutical Engagement

The Advocate: Supporting the Patient Voice has released its 2024 US Focused Patient Advocacy Report, which offers a detailed examination of the feedback from Patient Advocacy Organizations and Professional Societies/Associations, highlighting their interactions with the pharmaceutical industry. This report is essential for stakeholders seeking innovative ways to collaborate with these advocacy groups to enhance healthcare for patients.

Among over 100 companies evaluated, Johnson & Johnson (J&J) emerged as the top performer in advocacy, securing first place in five key categories. J&J was commended for its approach of moving 'beyond patient centricity to patient partner,' its willingness to collaborate with patient advocacy organizations beyond just providing funding, and its holistic strategy in building relationships and identifying collaborative opportunities for patient benefits.

Amgen also demonstrated significant progress, advancing in four out of five benchmarking categories. Patient advocates praised Amgen for being 'highly innovative and forward-thinking' and emphasized its engagement at multiple levels with patient advocacy groups to listen, learn, and understand the needs required to advance patient treatments.

Pfizer maintained a consistent performance since 2019, placing second in the areas of Advancing Patient Treatment and Patient/Professional Group Relations. Pfizer was recognized for its efforts in obtaining patient perspectives to advance care and improve access, as well as its commitment to patient support and educational advancement.

Sanofi showed notable improvements across various metrics, with patient advocates highlighting that 'patient engagement is second to none.' Sanofi was also recognized for fostering health equity education by forming communities of practice groups among patient organizations.

Other noteworthy organizations included AstraZeneca, which showed improvement in Policy Support, Eli Lilly, leading with Neurology groups, Merck, with impressive rankings among Non-disease Specific groups, and Bristol-Myers Squibb, which led the way with Immunology groups.

The Advocate: Supporting the Patient Voice aims to understand the relationship between patient advocates and the pharmaceutical industry, ensuring that patients remain at the center of healthcare decisions, whether in doctors' offices, within Payer or PBM walls, or on Capitol Hill. The organization aligns with the pharmaceutical community to ensure patients have access to necessary products and services. The Advocate achieves this through syndicated market research to gain insights into patient needs and the roles of patient advocate organizations.

The expertise of The Advocate enables them to guide pharmaceutical advocacy teams, aid in developing and implementing patient-centric programs within pharmaceutical companies, and consult on integrating the patient voice throughout a product's lifecycle. For more information, visit The Brooks Group Online.